Respiratory diseases are second only to cardiovascular conditions in terms of mortality, incidence and costs. Among the biggest causes of respiratory death in Europe are pneumonia and chronic obstructive pulmonary disease (COPD). Worldwide hundreds of millions of people suffer every day from chronic respiratory ill-health. According to the World Health Organisation (WHO) global estimates, 300 million people have asthma, 210 million people have COPD while millions more have allergic rhinitis and other, often under-diagnosed, chronic respiratory conditions.
Climate change is likely to have mostly adverse effects on health. These findings have been well described by the WHO. In Europe, as elsewhere, deaths from chronic respiratory and lung conditions are expected to increase in the future.
Despite the fact that emphysema and asthma often have no cure, nebulized solutions containing Hyaluronic Acid are helpful in the treatment of the main symptoms and – acting as an adjuvant therapy – they may reduce the need for bronchodilators; together with other more specific medications for each of the condition considered, this treatment is effective against both upper and lower airways, narrowing and enhancing ventilation and air flow to and from the lungs. On the other hand, the efficacy of N-Acetylcysteine as a mucolytic is widely known and drugs containing this active compound can cure symptoms in patients suffering from both acute and chronic bronchitis.
Rhinitis is another condition in which the use of nebulized Hyaluronic Acid is helpful, together with other medicaments such as antihistaminics and corticosteroids in the allergic type. Diclofenac, a cyclooxygenase inhibitor, which belongs to the category of nonsteroidal anti-inflammatory drugs (NSAIDs), is widely prescribed as an anti-inflammatory drug for the mouth and the throat.
IBSA offers a full range of mucolytics such as N-acetylcysteine. The pipeline in this therapeutic area has recently been enriched with other products containing hyaluronic acid for different respiratory diseases. Among these a HA solution for aerosol therapy is indicated for the restoration and maintenance of physiological conditions of the mucous membranes in upper and lower respiratory tract diseases.